2025 - Sustainable Industrial Processing Summit
SIPS2025 Volume 2. Inufusa Intl. Symp. / Oxidative Stress and Technological Innovations in Medicine
| Editors: | F. Kongoli, K. Abe, W. Cho, K. Fukui, S. Hirano, D. Joseph, T. Yoshikawa, J.R. Ribas, N. Tran |
| Publisher: | Flogen Star OUTREACH |
| Publication Year: | 2025 |
| Pages: | 282 pages |
| ISBN: | 978-1-998384-40-2 (CD) |
| ISSN: | 2291-1227 (Metals and Materials Processing in a Clean Environment Series) |
CD shopping page
OXIDATIVE STRESS AND ANTI-OXIDANT THERAPY DURING RADIOTHERAPY FOR HEAD AND NECK CANCERS
Davis Joseph1; Keiichiro Okano2; Shigeru Hirano2; Florian Kongoli3; Fuhua Yang1; Haruhiko Inufusa1;1GIFU UNIVERSITY, Gifu, Japan; 2KYOTO PREFECTURAL UNIVERSITY OF MEDICINE, Kyoto, Japan; 3FLOGEN TECHNOLOGIES, Mont-Royal, Canada;
Type of Paper: Keynote
Id Paper: 380
Topic: 54
Abstract:
Treatments for advanced head and neck cancer previously relied on radical surgery. However, radiation therapy and concurrent chemoradiotherapy, particularly using cisplatin, have gained preference due to their effectiveness and the preservation of normal tissues and their functions. A significant drawback of radiotherapy is its adverse effects, including oral mucositis, xerostomia, salivary gland dysfunction, neurological disorders, dysphagia, and dysphonia. Research in vitro, in vivo, and clinical trials has demonstrated that antioxidants effectively protect normal tissues from radiation-induced damage. However, the potential for antioxidants to compromise the tumoricidal efficacy of radiotherapy remains a subject of controversy. Clinical studies on head and neck cancer suggest that antioxidant use may negatively impact cancer control and survival outcomes. Consequently, non-selective systemic antioxidant therapy is not generally recommended. Recent advancements in the quantification of oxidative stress and biological antioxidant potential provide new opportunities to customize antioxidant therapies for individual patients. To optimize outcomes, further research is needed to elucidate the complex interactions between antioxidants, reactive oxygen species (ROS), and tumors. The development of novel antioxidant agents that can selectively protect normal tissue is also required. Subsequently, large-scale randomized controlled trials will be necessary to evaluate the efficacy of antioxidant therapies tailored to tumor characteristics and the specific conditions of individual patients. Below is the first part series of a work in progress regarding combinative antioxidant-proapoptotic therapies for head and neck cancer patients during radiotherapy.